IMA Wealth Inc. Purchases Shares of 12,348 Zoetis Inc. (NYSE:ZTS)

IMA Wealth Inc. purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,348 shares of the company’s stock, valued at approximately $2,437,000.

A number of other institutional investors have also bought and sold shares of the company. Cary Street Partners Investment Advisory LLC boosted its position in shares of Zoetis by 7.4% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC bought a new position in shares of Zoetis during the 4th quarter worth about $2,776,000. BLB&B Advisors LLC boosted its position in shares of Zoetis by 1.9% during the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after purchasing an additional 1,107 shares in the last quarter. Ninety One UK Ltd boosted its position in shares of Zoetis by 13.1% during the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after purchasing an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after purchasing an additional 17,976 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. The Goldman Sachs Group upped their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday. Stifel Nicolaus lowered their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $218.00.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 2,209 shares of company stock worth $371,293 in the last quarter. Insiders own 0.12% of the company’s stock.

Zoetis Stock Up 3.3 %

NYSE:ZTS traded up $5.06 on Friday, hitting $158.42. The stock had a trading volume of 5,236,463 shares, compared to its average volume of 4,019,007. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The stock has a market cap of $72.45 billion, a P/E ratio of 31.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s fifty day simple moving average is $171.79 and its two-hundred day simple moving average is $179.29.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the previous year, the business earned $1.15 EPS. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts predict that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s payout ratio is currently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.